FDA Approves New Treatment Option For Chronic Graft-Versus-Host-Disease In Patients Ages 12 Years And OlderPosted On: August 3, 2021
Rye Brook, N.Y., August 3, 2021 - The U.S. Food and Drug Administration (FDA) recently approved belumosudil (Rezurock™) in patients 12 years or older for the treatment chronic graft-versus-host-disease (GvHD) that has not responded or has stopped responding to earlier treatments.Read More
Rye Brook, N.Y., August 3, 2021 - The U.S. Read More
LLS Urges Blood Cancer Patients to get Vaccinated as its National Patient Registry Enters Next Phase in COVID-19 Vaccine StudiesPosted On: July 15, 2021
Rye Brook, N.Y., July 15, 2021—The Leukemia & Lymphoma Society® (LLS) began recruitment this week for a new study evaluating T-cell immune response to COVID-19 vaccine among people with a current or past diagnosis of blood cancer. This invitation-only follow-up study will include a sub-set of participants from a larger LLS study examining COVID-19 spike antibody response to vaccination. Both studies are being conducted as part of the LLS National Patient Registry, a project of the Michael J. Garil Patient Data Collective.Read More
Rye Brook, NY, June 23, 2021 - The U.S. Food and Drug Administration (FDA) last week approved avapritinib (Ayvakit®) for the treatment of advanced systemic mastocytosis (SM) in adults, including patients with aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia. Avapritinib is a targeted treatment that inhibits a mutation in the KIT gene, which drives about 95% of the cases of this rare type of blood cancer.Read More
WASHINGTON, D.C, June 17, 2021 – 34 patient organizations representing millions of people living with serious and chronic health conditions issued the following statement regarding the Supreme Court’s ruling upholding the Affordable Care Act:Read More
Please send all media-related inquiries and interview requests to firstname.lastname@example.org. An LLS representative will respond as soon as possible.